Clinical Trial Update: Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study of MLN4924 (pevonedistat), a Nedd8-activating enzyme inhibitor, in adults with lymphoma or multiple myeloma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Lymphoma
• Multiple Myeloma

Drugs mentioned

• MLN4924 (pevonedistat)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Hematologic Malignancies, Multiple Myeloma | Phase 1 | Status: COMPLETED